Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

CAPS Rating: 4 out of 5

Caps

How do you think ADVM will perform against the market?

Add Stock to CAPS Watchlist

All Players

29 Outperform
2 Underperform
 

All-Star Players

8 Outperform
2 Underperform
 

Wall Street

0 Outperform
1 Underperform
 

Top ADVM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

q10 (< 20)
Submitted December 20, 2017

ready to take off

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

ADVM VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ADVM.

Recs

0
Member Avatar Bigsef77 (71.60) Submitted: 9/21/2018 4:29:03 PM : Outperform Start Price: $3.25 ADVM Score: +76.32

Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD
GlobeNewswire•September 19, 2018
ADVM-022 is a unique single-administration gene therapy delivered intravitreally for the treatment of wAMD
OPTIC Phase 1 clinical trial initiation expected in 4Q18
MENLO PARK, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ADVM-022. ADVM-022 is a novel gene therapy candidate for the treatment of wet age-related macular degeneration (wAMD).

“The FDA’s Fast Track designation is an important recognition of our ADVM-022 gene therapy program,” said Leone Patterson, interim president and chief executive officer of Adverum Biotechnologies. “We look forward to working with the FDA and benefiting from the potential expedited development and regulatory path offered by their Fast Track program.”

A Fast Track designation is intended to facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill unmet medical needs. The designation enables more frequent communication with the FDA throughout a product candidate’s development and review process. The designation also provides eligibility for Priority Review and Accelerated Approval, which may potentially result in a shorter FDA review process.

Recs

0
Member Avatar jclaypool (45.99) Submitted: 8/30/2018 6:09:33 AM : Outperform Start Price: $6.50 ADVM Score: -7.63

New products are going into clinical trials.

Recs

1
Member Avatar q10 (< 20) Submitted: 12/20/2017 10:25:24 AM : Outperform Start Price: $3.35 ADVM Score: +70.30

ready to take off

Leaderboard

Find the members with the highest scoring picks in ADVM.

Score Leader

WalkingCaptain

WalkingCaptain (< 20) Score: +125.19

The Score Leader is the player with the highest score across all their picks in ADVM.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Bigsef77 71.60 12/19/2017 Outperform 1Y $3.25 +84.62% +8.29% +76.32 1 Comment
Momentum21 93.32 12/8/2017 Outperform 5Y $3.30 +81.82% +9.72% +72.10 0 Comment
q10 < 20 12/20/2017 Outperform 5Y $3.35 +79.10% +8.81% +70.30 1 Comment
stainsolution 45.87 1/2/2018 Outperform 5Y $3.65 +64.38% +8.55% +55.83 0 Comment
Jordrok 88.60 2/13/2018 Underperform 1Y $6.75 -11.11% +10.15% +21.26 0 Comment
aleksandrk 37.70 5/6/2016 Outperform 5Y $4.46 +34.53% +41.95% -7.42 0 Comment
jclaypool 45.99 8/30/2018 Outperform 5Y $6.50 -7.69% -0.07% -7.63 1 Comment
vectorplexus 34.25 4/10/2018 Outperform 5Y $5.98 +0.42% +10.08% -9.66 0 Comment
Plasmidologist 31.66 1/29/2018 Outperform 5Y $7.50 -20.00% +2.15% -22.15 0 Comment
sublimeinvestor 30.44 1/29/2018 Outperform 5Y $7.50 -20.00% +2.15% -22.15 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.76 3/23/2015 Underperform 3W $43.07 -86.07% +38.45% +124.52 0 Comment

Featured Broker Partners


Advertisement